PD-L1 Protein (DYKDDDDK-His Tag)

N° du produit ABIN2713589

Protéine Recombinant PD-L1 exprimée dans HEK-293 Cells.

Aperçu rapide pour PD-L1 Protein (DYKDDDDK-His Tag) (ABIN2713589)

Antigène: PD-L1 (CD274 (PD-L1))

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Application: Antibody Production (AbP), Standard (STD)

Pureté: > 80 % as determined by SDS-PAGE and Coomassie blue staining

Détail du produit

Purification/Conjugué: Cette PD-L1 protéine est marqué à la DYKDDDDK-His Tag.

Attributs du produit:

• Recombinant human CD274 / PDL1 (C-term DDK/His tag, transcript variant 1) protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Information d'application

Indications d'application: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Commentaires:

The tag is located at the C-terminal.

Restrictions: For Research Use only

Stockage

Concentration: 50 μg/mL

Buffer: DPBS, 10 % glycerol

Stock: -80 °C

Stockage commentaire: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Détail du antigène

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: Cd274,pdl1

Sujet: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

Poids moléculaire: 33.28

NCBI Accession: NP_054862

Pathways: Cancer Immune Checkpoints